Pharmacokinetic (PK) modeling for peptide molecules differs in important ways from the small-molecule paradigm that dominates pharmacology textbooks. Peptides are generally hydrophilic, charged, and protease-susceptible; their distribution and elimination profiles are dominated by proteolysis and renal handling rather than by hepatic cytochrome P450 metabolism. The classical compartmental modeling assumptions developed for small molecules require careful re-examination before being applied to peptide drugs.
The principal PK challenges for peptide therapeutics fall into four categories. Absorption: oral bioavailability is typically under 1% without permeation-enhancement or absorption-enhancing formulations (the salcaprozate sodium technology used in oral Semaglutide is an instructive case study). Distribution: most peptides are confined to the vascular compartment and interstitial fluid; CNS penetration generally requires either active transport, intranasal delivery, or substantial molecular engineering. Metabolism: degradation is driven by ubiquitously expressed peptidases rather than by the hepatic cytochrome system, complicating species-translation. Elimination: renal filtration dominates for peptides below ~30 kDa, whereas larger molecules are processed through receptor-mediated endocytic clearance.
Modern peptide drug design accordingly emphasizes strategies to extend circulating half-life: D-amino-acid substitution at protease cleavage sites, cyclization to constrain proteolytically vulnerable geometries, PEGylation, fatty-acid attachment for albumin binding (the strategy that converts native GLP-1’s six-minute half-life into Semaglutide’s seven days), and fusion to Fc domains or albumin-binding scaffolds. Each strategy has tradeoffs in receptor affinity, immunogenicity, and manufacturing complexity that the PK modeler must account for from the earliest stages of program design.